Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Without releasing specific figures, Pfizer said Monday that treatment with ... Pfizer said it plans to discuss with the FDA the potential for full approval of Braftovi in metastatic colorectal ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo ... improvement in overall survival (OS), a key secondary endpoint in ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous ...

NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced key executive appointments designed to accelerate the ...

In addition to a suite of big deals announced Monday, the 2025 J.P. Morgan Healthcare ... Ordspono, an antibody used for treating lymphoma, is already approved in the EU and Regeneron is preparing ...